These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38281296)

  • 1. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
    Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
    Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases.
    Liu D; Chang L; Zhao X; Dai L; Cui H; Liu P; Zhai Z; Wu H; Ma X; Kang H
    Clin Breast Cancer; 2024 Jun; 24(4):e232-e243.e1. PubMed ID: 38368246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.
    Gao W; Lu S; Zeng Y; Chen X; Shen K
    Breast Cancer Res Treat; 2022 Nov; 196(1):129-141. PubMed ID: 36076127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Axillary Lymph Node Dissection be Omitted in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes Undergoing Mastectomy? A Systematic Review and Meta-Analysis of Real-World Evidence.
    Chen F; Li X; Lin X; Chen L; Lin Z; Wu H; Chen J
    World J Surg; 2023 Oct; 47(10):2446-2456. PubMed ID: 37249632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
    Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
    Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
    Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
    Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
    Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary management based on American college of surgeons oncology group Z0011 criteria makes it possible to omit intraoperative diagnosis of sentinel lymph nodes in early breast cancer patients.
    Kittaka N; Nakajima S; Hatano T; Seto Y; Kusama H; Matsui S; Nishio M; Fujisawa F; Honma K; Nakayama T; Tamaki Y
    Breast J; 2021 Nov; 27(11):804-810. PubMed ID: 34558164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intraoperative assessment of sentinel nodes - Standards and controversies.
    van der Noordaa MEM; Vrancken Peeters MTFD; Rutgers EJT
    Breast; 2017 Aug; 34 Suppl 1():S64-S69. PubMed ID: 28673534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.